Oestrogen Pre‐treatment Abolishes Luteinising Hormone‐Releasing Hormone Testosterone Stimulation

W. KREIS, F. R. AHMANN, V. C. JORDAN, H. de HAAN, M. SCOTT

Research output: Contribution to journalArticle

12 Scopus citations

Abstract

Summary— In patients with histologically confirmed prostate cancer, oestrogen priming with diethylstilboestrol (DES) (3 mg/day) for 4 weeks prior to the first injection of the LHRH agonist Zoladex (3.6 mg depot form) prevented any rise in the serum testosterone concentration. In contrast, in the groups pre‐treated with DES, the first, but not subsequent, injections with Zoladex were associated with a marked surge in luteinising hormone. Treatment with DES beyond the time of the first administration of Zoladex did not provide further endocrinological advantage. Oestrogen priming for 1 month prior to treatment with Zoladex may prevent an exacerbation of signs and symptoms of prostate cancer.

Original languageEnglish (US)
Pages (from-to)352-354
Number of pages3
JournalBritish Journal of Urology
Volume62
Issue number4
DOIs
StatePublished - Oct 1988

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'Oestrogen Pre‐treatment Abolishes Luteinising Hormone‐Releasing Hormone Testosterone Stimulation'. Together they form a unique fingerprint.

Cite this